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Abstract: The optimal treatment of schizophrenia poses a challenge to develop more effective 
treatments and safer drugs, to overcome poor compliance, discontinuation and frequent 
switching with available antipsychotics. Iloperidone is a new dopamine type 2/serotonin 
type 2A (D2/5-HT2A) antagonist structurally related to risperidone, expected to give better 
efficacy with less extrapyramidal symptoms than D2 receptor antagonist antipsychotics. 
In double-blind phase III trials iloperidone reduced the symptoms of schizophrenia at oral 
doses from 12 to 24 mg. It was more effective than placebo in reducing positive and nega-
tive syndrome total score and Brief Psychiatric Rating scale scores; it was as effective as 
haloperidol and risperidone in post-hoc analysis. Its long-term efficacy was equivalent to 
that of haloperidol. The most common adverse events were dizziness, dry mouth, dyspepsia 
and somnolence, with few extrapyramidal symptoms and metabolic changes in short- and 
long-term studies in adults. Akathisia was rare, but prolongation of the corrected QT (QTc) 
interval was comparable to haloperidol and ziprasidone, which is of particular concern. 
Further comparative studies are needed to clarify the benefit/risk profile of iloperidone and 
its role in the treatment of schizophrenia.
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Introduction
Schizophrenia is a severely debilitating psychiatric disorder observed worldwide, 
with a median lifetime prevalence of 0.7%–1.0%.1 It causes recurring and progressive 
episodes of positive and negative symptoms, disturbed cognitive function and other 
abnormalities.2,3 This disorder is associated with an increased risk of mortality3 and 
imposes a huge financial burden on society,4 although with striking differences in 
the annual cost of care per patient between and within different countries.5 Optimal 
treatment of the disease could lessen this burden6 but it is still challenging to develop 
effective, safe antipsychotic drugs. Although many antipsychotics are currently 
available, the treatment response varies widely. Moreover, predicting the response is 
still hampered by many methodological and clinical problems and is not possible for 
clinicians in their prescribing practice.7
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) showed 
that antipsychotic treatment was marked by poor compliance, drug discontinuation 
and frequent switching attributable to lack of efficacy and intolerance in patients 
with chronic schizophrenia; this was true for the older, conventional antipsychotics 
(commonly defined as “first-generation” antipsychotics) as well as the second-
generation drugs introduced in recent years, the so-called “atypical antipsychotics”.8Drug Design, Development and Therapy 2010:4 34
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Conventional antipsychotics such the well-known 
phenothiazines (eg, chlorpromazine), butyrophenones 
(eg, haloperidol) and diphenylbutylpiperidine derivatives 
(eg, pimozide) are used as first-line therapy for schizo-
phrenia although this is changing and second-generation 
drugs, introduced after the archetype clozapine, are now the 
mainstay of treatment in several countries. As a general rule 
first-generation agents are antagonists at the dopamine type 2 
(D2) receptors and their clinical efficacy is strongly correlated 
between with their binding affinities for the receptor subtype.9 
The dopaminergic theory holds that this is possibly because 
the disease is due to alterations in central dopaminergic 
transmission, with increased dopamine transmission in the 
mesolimbic pathway leading to positive symptoms, and 
reduced dopamine transmission in the mesocortical pathway 
explaining negative symptoms.
Although the neurochemical origins of schizophrenia 
do not necessarily lie in this dopamine dysregulation, this 
is the final common pathway underlying positive psychotic 
symptoms and may also play a role in negative and cognitive 
symptoms.10 Accordingly, the blockade of dopamine receptors 
in the mesolimbic pathway by these antipsychotics controls 
positive symptoms in a substantial proportion of patients.11 
However, these drugs offer little benefit in controlling nega-
tive symptoms or cognitive deficits, and can result in extra-
pyramidal symptoms (EPS) and a progressively increasing 
risk of tardive dyskinesia.12,13 Prolactin elevation, which can 
lead to sexual side effects, is also a frequent adverse reac-
tion to these drugs, and occurs with some second-generation 
antipsychotics too.14
Besides being dopamine receptor antagonists, second-
generation antipsychotics have an additional range of binding 
activity at various other receptor sites. While each drug has 
its own receptor profile, most of them show higher affinity 
for serotonin type 2A (5-HT2A) than D2 receptors (exceptions 
are the dopamine-D2 and -D3 receptor antagonist amisulpride 
and the partial dopamine agonist, or mixed agonist-antagonist 
at cerebral D2 receptors aripiprazole); this ratio of affinities 
has been suggested to account for their enhanced efficacy and 
lower rates of EPS.15,16 The blockade of 5-HT2A receptors may 
partly reduce the blockade of dopamine transmission. Fewer 
EPS and lower risk of tardive dyskinesia would result from 
the reversed D2 blockade in the striatum, although the CATIE 
study found that there is still 4%–8% EPS even with these 
newer agents.8,12 Antagonism at 5-HT2A receptors in the meso-
cortical pathway and the consequent increase in dopamine 
transmission in the prefrontal cortex has also been suggested 
to account for the efficacy against negative symptoms.15
However, like first-generation antipsychotics, these 
newer agents are not free of side effects such as weight 
gain, hyperglycemia and dyslipidemia; drug-related cardiac 
changes (QTc prolongation) have also been reported.12 This 
and the above limitations8 have prompted a continuing effort 
to develop more effective and safer antipsychotics that could 
improve outcomes for schizophrenic patients. Whereas some 
of these “newer” antipsychotics are still in the premarketing 
stage,17 others have already joined the second-generation 
therapies. This latter group includes the mixed D2/5-HT2 
antagonist iloperidone whose efficacy in the treatment of 
schizophrenia, reassuring metabolic and safety profiles have 
been established in double-blind placebo-controlled clinical 
trials.18,19 This review analyzes the pharmacological profile, 
clinical efficacy and tolerability of this new antipsychotic in 
adults with schizophrenia.
Data sources and selection 
of studies
Using the keywords iloperidone, and schizophrenia a litera-
ture search was undertaken, using the international database 
PubMed, to find all the studies published in English. No 
date constraints were utilized. Data were also collected 
from the product labelling available at http://www.fanapt.
com (accessed on September 2009). A query iloperidone 
on http://www.clinicaltrials.gov and http://fda.gov did not 
produce any other completed clinical studies. From PubMed 
we identified 33 records that matched the two key-words: 
four were phase III clinical trials and three pharmacogenetic 
studies.
Pharmacological profile
Chemically, iloperidone (HP 873; ILO-522; 1-[4-[3-[4-
(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-
3-methoxyphenyl]ethanone) is a piperidinyl-benzisoxazole 
derivative structurally related to risperidone (see Figure 1), 
the first of the post-clozapine antipsychotics to become 
widely available. It was selected from a large series of 
piperidinyl-benzisoxazoles because it showed 300-times 
more potency in a test for limbic activity (inhibition of 
apomorphine-induced climbing) than in a test for nigrostria-
tal activity (inhibition of apomorphine-induced stereotypy). 
The large difference of potency in these tests was expected 
to result in a better ratio of therapeutic effect to EPS liability 
compared with standard antipsychotics.20 In a similar 
chemical class are ziprasidone and other benzisothiazole 
derivatives with antipsychotic activity. Besides the chemical Drug Design, Development and Therapy 2010:4 35
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structure, benzisothiazoles and benzisoxazoles share some 
minor metabolic pathways.21
Like risperidone, ziprasidone, and other atypical anti-
psychotics, iloperidone adheres to the 5-HT2A/D2 receptor 
hypothesis15 in that it has higher affinity for the 5-HT2A recep-
tor (Ki  10 nM) than for the D2 receptor Ki = 10–100 nM).22,23 
As mentioned, in theory it should have greater efficacy 
and fewer EPS than first-generation antipsychotic drugs.15 
Iloperidone, however, is different as it binds to other serotonin 
receptors. It has moderate affinity for 5-HT1A, 5-HT2C, and 
5-HT6 (KI: 10–100 nM), behaving as an antagonist at 5HT2C 
and 5HT6 receptors, and as a partial agonist at 5HT1A. With 
other dopamine receptor subtypes, it showed high affinity 
for the dopamine type 3 receptor and moderate affinity for 
the dopamine type 4 receptor.22–25
In addition to its affinities for serotonin and dopamine 
receptors, iloperidone has high affinity for alpha1 receptors 
(Ki  10 nM) and moderate affinity for alpha2C receptors. 
Blockade of these receptors may contribute to the drug’s 
efficacy, particularly on mood and cognition, although it may 
also cause postural dizziness or orthostatic hypotension23,25 
Blockade of α2C adrenoceptors might translate into antide-
pressant and anxiolytic activity.23
The affinity for all other receptors was low, includ-
ing norepinephrine alpha(2A), alpha(2B), beta(1), and 
beta(2), dopamine D(1) and D(5), CCK(A) and CCK(B), 
5-HT(7), dopamine and norepinephrine transporters. 
Interestingly, iloperidone had little affinity for cholinergic 
muscarinic receptors M1–M5, so it is not likely to have 
anticholinergic effects. Iloperidone also displayed low 
affinity for the histamine H1 receptors23 and has in fact little 
effect on body weight (see below), although some other 
neurotransmitter may be involved in the less severe weight 
gain potential than with other antipsychotics.26
The potential clinical efficacy of iloperidone was also 
predicted through a series of behavioural studies in animal 
models. These included the apomorphine-induced climbing 
mouse paradigm, the 5-HT-induced head twitch and pole 
climb avoidance in rats and continuous Sidman avoidance 
responding in monkeys.27 Consistent with iloperidone’s effect 
in reversing elevated acoustic startle in both cirazoline-treated 
and isolation-reared rats,28 it had anxiolytic-like properties 
in the elevated plus maze in rodents and in preclinical assays 
predictive of efficacy in social interaction.27,29 Importantly, 
it showed only minimal activity in tasks predictive of EPS 
liability.20,27 Findings have been reviewed elsewhere.17,30,31
More recently, iloperidone was shown to improve rat 
choice accuracy in a delayed non-matching-to-position 
paradigm, suggesting a specific effect on working memory, 
although measures of task performance did not improve. 
In comparison, clozapine had no effect on choice accuracy 
and did not affect non-mnemonic parameters, except for the 
number of omissions at the higher dose. Haloperidol, on 
the other hand, impaired most non-mnemonic parameters, 
Figure 1 Chemical structures of iloperidone, risperidone, paliperidone (9-hydroxyrisperidone) and ziprasidone.Drug Design, Development and Therapy 2010:4 36
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especially at higher doses, and tended to have a detrimental 
effect on choice accuracy.32
Pharmacokinetics
Iloperidone is rapidly absorbed reaching peak concentra-
tions between 2 and 5 hours after oral doses in healthy 
subjects and renally and hepatically impaired patients.33,34 
It’s pharmacokinetics were linear after doses of 3 and 5 mg 
in healthy subjects.34 However, some nonlinearity was seen 
in schizophrenic patients over the dosage range of 2–12 mg 
bid, although its main metabolites (see below) had linear 
pharmacokinetics.34 The relative bioavailability of the tablet 
formulation compared to oral solution was 96% in healthy 
subjects.33,34
Food (standard breakfast) did not significantly affect the 
bioavailability of iloperidone in healthy subjects, only slightly 
delaying its rate of absorption (and the rate of appearance of 
its main metabolites).35 Therefore like most antipsychotics, 
iloperidone can be administered without regard to meals. 
However, the administration of ziprasidone with food 
approximately doubles its absolute availability, and a high-
carbohydrate, high-fluid diet almost halves the already low 
oral bioavailability of amisulpride, although a high-fat meal 
did not alter its absorption (for review see 21).
Once absorbed, iloperidone rapidly distributes in 
tissues, as evidenced by the large volume of distribution 
of 1340–2800 L.33,34 Brain uptake is extensive,36 like most 
antipsychotics except substrates of the efflux transporter 
P-glycoprotein such as risperidone.37 Binding to plasma pro-
teins is about 93% over the concentration range 5–500 ng/mL 
(reviewed in36,38) and is unchanged by renal impairment 
(97%) or hepatic impairment (97%).33,34
Like most antipsychotics iloperidone undergoes extensive 
presystemic elimination and is cleared through multiple met-
abolic pathways mediated by different enzymes (exceptions 
are amisulpride and paliperidone whose clearance are largely 
trough urinary excretion; see for reviews21,39). In a reversible 
step, the iloperidone acetophenone ring structure (1, in Figure 
2) is reduced to form reduced iloperidone (P88-8991; 2).40,41 
Cytosolic enzymes are most likely the primary system by 
which this occurs, although CYP1A2, CYP2E1 and CYP3A4 
may also play a role.41 Reduced iloperidone crosses the blood-
brain barrier and shows high affinity for serotonin 5-HT2A, 
adrenergic alpha1, alpha2C and dopamine D2 receptors, similar 
to the parent drug, with equal affinity for the alpha2C and D2 
receptors.42 After a single 3 mg oral dose in CYP2D6 normal 
metabolizers (EM) and poor metabolizers (PM) it reached 
plasma Cmax comparable to those of the parent drug. Mean 
plasma area under the curve (AUC) was higher in PM than 
in EM but exposure to reduced iloperidone was higher than 
to iloperidone in both populations, suggesting that the active 
metabolite is likely to account for a substantial part of the 
drug’s clinical profile (Table 1).
Reduced iloperidone is primarily cleared by glucuronida-
tion,41 with elimination half-lives (t1/2) of 25.5 and 37.3 hours 
respectively in EM and PM, after 3 mg iloperidone orally.34 
At this dose, in these populations, the elimination t1/2 of ilo-
peridone were 17.6 hours and 32.8 hours,34 therefore it must be 
assumed that steady-state concentrations of the active forms 
are attained within 5–6 days of dosing. Unpublished studies 
suggest that at steady state reduced iloperidone accounts for 
19.5% and 34% of total plasma exposure (iloperidone plus 
metabolites) although results were not detailed.33
CYP2D6-mediated oxidation of the ethanone part 
of the molecule results in the α-hydroxy ketone (4, in 
Figure number 2), which is converted (the mechanism is still 
under investigation)41 to the other major circulating metabo-
lite, P95-12113 (Figure number 5), in human plasma.33,34 
This metabolite has poor in vitro activity at the 5-HT2A and 
noradrenaline alpha1 and alpha2 receptors.42 It reached higher 
plasma concentrations in CYP2D6 EM than in CYP2D6 PM 
after 3 mg iloperidone (Table 1),34 representing 48% of the 
iloperidone plasma AUC in EM and 25% in PM at steady 
state.33 However, it does not cross the blood-brain barrier in 
rodents and therefore it probably only contributes to periph-
eral side effects of iloperidone.42 In contrast, the primarily 
oxidized metabolite of risperidone, 9-hydroxyrisperidone, 
which accounts for most of total risperidone exposure, 
essentially retains the central activity of the parent drug 
(reviewed in21,43) and has been recently approved as the new 
antipsychotic drug paliperidone.
Other oxidative routes include the CYP3A4-mediated 
O-demethylation of the acetophenone ring structure 
(Table 1 number 3). Metabolites are then eliminated through 
further oxidation and conjugation with glucuronic acid.40,41 
Excretion is mainly renal, with about 58.2% and 45.1% of 
radioactive iloperidone recovered in urine of EM and PM; 
feces contribute for 19.9% (EM) to 22.1% (PM) of total 
radioactivity.33
Drug interactions
The importance of CYP2D6 in iloperidone clearance is 
underlined by its interaction with potent inhibitors of these 
enzymes (no inducers are known at present). Fluoxetine 
(20 mg twice daily for 21 days with 3 mg iloperidone to 
healthy subjects) raised the plasma AUC of iloperidone Drug Design, Development and Therapy 2010:4 37
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Figure 2 Main metabolic pathways of iloperidone.
and its reduced form by 137% and 121% respectively, and 
lowered the AUC of its main oxidized metabolite by 53% 
when administered. However, iloperidone did not alter the 
pharmacokinetics of fluoxetine and its active metabolite 
norfluoxetine.33,34
Similarly, co-administration of paroxetine (20 mg/day for 
5–8 days) with multiple doses of iloperidone (8 or 12 mg twice 
daily) to patients with schizophrenia raised mean steady-
state peak concentrations of iloperidone and its reduced 
metabolite about 1.6-fold, and halved mean steady-state 
peak concentrations of the main inactive metabolite.33,34 
However, there were no clinically relevant effects on the 
pharmacokinetics of dextromethorphan (80 mg, a CYP2D6 
substrate) when given concomitantly with iloperidone (3 mg) 
in healthy subjects, suggesting that interactions between 
iloperidone and other CYP2D6 substrates are unlikely.33
Although CYP3A4-mediated O-demethylation is a 
minor metabolic pathway, with minimal concentrations of Drug Design, Development and Therapy 2010:4 38
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O-desmethyl iloperidone present in human plasma after 
oral iloperidone, the potent CYP3A4 inhibitor ketoconazole 
(200 mg twice daily for 4 days) raised the AUC of iloperidone 
(3 mg) by 57% and that of its active and inactive metabo-
lites by 55% and 35%, respectively.33,34
Importantly, a QTc (corrected QT) prolongation of 
9 milliseconds was reported after 12 mg b.i.d iloperidone 
in patients with schizophrenia or schizoaffective disorder, 
with an increase in the mean QTc from baseline of about 
19 milliseconds when the drug was given concomitantly with 
paroxetine (20 mg/day) and ketoconazole (200 mg twice daily). 
Therefore iloperidone doses should be halved when admin-
istered with strong inhibitors of CYP2D6 or CYP3A4, in 
view of the potential for QT interval prolongation subsequent 
to increased exposure to iloperidone and metabolites.33,34
Judging from in vitro studies, iloperidone is not a substrate 
for other CYP enzymes generally involved in drug metabolism. 
This suggests it is unlikely to interact with drugs that inhibit 
or induce these enzymes.33 Also, smoking should not affect 
its pharmacokinetics, like most antipsychotics except the 
CYP1A2 substrates clozapine and olanzapine whose clear-
ance is affected by cigarette smoking and drugs that induce 
or inhibit CYP1A2.21 In vitro studies in human liver micro-
somes showed that iloperidone do not induce CYP1A2, 
CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP3A5.33
Efficacy
The efficacy of iloperidone in patients with schizophrenia 
(DSM-III/IV criteria) has been established in nine integrated 
clinical studies: two phase II,44,45 four pivotal phase III and 
three long-term efficacy trials.46–50
Phase ii
In the first six-week phase II study, 104 hospitalized patients 
with acute or relapsing schizophrenia were enrolled in a 
placebo-controlled trial and received a fixed dose of either 
4 or 8 mg/day of iloperidone, after titration over 3–10 days. 
Although both iloperidone groups improved, the 8 mg/day 
group showed a significant improvement in comparison with 
placebo, with a mean total score reduction of 18 points of the 
Positive and Negative Syndrome Scale (PANSS). No other 
efficacy scores were statistically significant.44,45
Another phase II study investigated the maximum toler-
ated once-daily dose of iloperidone and checked orthostatic 
blood pressure. Twenty-four out-patients with schizophrenia 
were enrolled to receive iloperidone at dosages of 2, 4, 6, 8, 
12, 16, 20, 28 and 32 mg, with increases every three days, 
or 1, 2, 4, 8, 12, 16, 20 and 24 mg with dose titration every 
two days, or the latter dosage range, but with dose titration 
every day. In each group the highest dosage was continued 
for four days. Doses of iloperidone up to 32 mg/day were 
well tolerated.44,46
Phase iii
Table 2 summarizes the phase III clinical trials. All eligible 
patients had a diagnosis of schizophrenia according to 
Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV) criteria. When specified, exclusion criteria 
included: history or diagnosis of chemical dependence, 
recreational drug or alcohol use, toxic psychosis in the last six 
months, imminent risk of suicide, major neurological deficit, 
congenital disorder, congenital QT-syndrome, psychotic 
symptoms that had not improved after adequate treatment 
with two antipsychotics in the preceding two years. Iloperi-
done was given orally twice daily with titration according 
to the manufacturer’s prescribing information. Comparator 
drugs were given at recommended target dosages.
Short-term efficacy
Three pivotal phase III clinical trials (study 1, study 2, and 
study 3) evaluated the short-term efficacy of iloperidone.47 All 
were six-week, randomized, double-blind, placebo- and active 
comparator-controlled trials in patients with acute or subacute 
exacerbation of schizophrenia or schizoaffective disorders. 
After pre-randomization screening and a single-blind three-
day placebo run-in, patients were randomized to iloperidone 
(seven-day fixed titration period followed by five weeks of 
maintenance therapy), active control, or placebo. Patients in 
study 1 randomly received iloperidone 4, 8 and 12 mg/day 
or haloperidol 15 mg/day, or placebo. The randomization in 
study 2 was for iloperidone (4 to 8 mg/day or 10 to 16 mg/
day), risperidone (6 to 8 mg/day) or placebo. In study 3, 
patients were randomized to iloperidone (12 to 16 mg/day 
Table 1 exposure to iloperidone and its main metabolites in 
extensive and poor CYP2D6 metabolizers after single oral doses 
Compound Metabolizers at CYP2D6
EM PM
Cmax  
(ng/mL)
AUC  
(ng.h/mL)
Cmax  
(ng/mL)
AUC    
(ng.h/mL)
iloperidone 2.79 (27) 29.4 (36) 2.26 (13) 46.3 (17)
Metabolite 2a  2.32 (30) 49.4 (43) 3.33 (20) 96.4 (21)
Metabolite 5b 4.50 (34) 153.8 (26) 0.67 (44) 32.1 (36)
Means with (Cv%); the dose of iloperidone was 3 mg.34
aP88-8991, reduced iloperidone; bP-95-12113, carboxyl acid derivative (see Figure 1 
for chemical structure).41
Abbreviations: eM, extensive metabolizers; PM, poor metabolizers.Drug Design, Development and Therapy 2010:4 39
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or 20 to 24 mg/day), risperidone (6 to 8 mg/day) or placebo. 
All drugs were given twice daily. The primary efficacy 
measure was the change from baseline to end-point in 
PANSS-total (PANSS-T) scores and in the Brief Psychiatric 
Rating Scale (BPRS). Results were determined with an 
intent-to-treat (ITT) population, which included patients who 
had received at least one dose of the study medication and 
had at least one complete PANSS assessment, using the last 
observation carried-forward (LOCF) method.
At least one iloperidone dosing group was significantly 
more efficacious than placebo in each study. In study 1, 
12 mg/day reduced on the PANSS-T score by 9.9, which 
was significantly different from the 4.6-point reduction 
observed with placebo (P = 0.047). There were no significant 
differences between iloperidone 4 mg/day or 8 mg/day and 
placebo. Patients treated with haloperidol 15 mg/day had a 
mean reduction of 13.9 points (P  0.001) in the PANSS-T 
score. In studies 2 and 3 there was significant improvement 
from baseline in BPRS scores at all iloperidone doses and 
for risperidone. Compared with placebo these changes were 
significant for both doses of iloperidone in study 2, and for 
iloperidone 20 to 24 mg/day in study 3. A combined analysis 
of all eligible patients (n = 1553) showed that each dose of 
iloperidone or active comparator was significantly more 
effective than placebo.
An additional four-week, phase 3 trial evaluated the effi-
cacy of iloperidone in hospitalized patients with acute psy-
chotic exacerbation of schizophrenia.49 A total of 593 subjects 
aged 18–65 years with a baseline PANSS-T score 70, 
a Clinical Global Impression-Severity (CGI-S) score 4, 
and a PANSS positive (PANSS-P) score 4 for at least two 
among delusions, conceptual disorganization, hallucinations, 
and suspiciousness/persecution, were randomized to receive 
iloperidone, ziprasidone or placebo. The dosage for active 
treatment was titrated over the first week (iloperidone 1, 2, 
4,6,10, and 12 mg twice daily titrated sequentially each day 
on days 1 to 7; ziprasidone 20 mg twice daily on days 1 and 
2, 40 mg twice daily on days 3 and 4, 60 mg twice daily 
on days 5 and 6, and 80 mg twice daily on day 7); placebo 
was administered twice daily. The study was not designed 
as a head-to-head comparison between iloperidone and 
ziprasidone.
Patients in the three groups had similar completion 
rates (iloperidone 65%; ziprasidone 66%; placebo 60%), 
and withdrawal of consent was the most frequent reason 
for early discontinuation, followed by unsatisfactory thera-
peutic effect and adverse events. There was a significant 
reduction from baseline to endpoint in PANSS-T scores 
with iloperidone (–12.0; P = 0.006) and ziprasidone (–12.3; 
P = 0.012) compared with placebo (–7.1, which is a low 
placebo response). Furthermore, iloperidone worked for both 
the positive and negative clusters of symptoms, and all the 
secondary rating scales were statistically better with iloperi-
done than with placebo. Rates of response for ziprasidone 
were not reported.
In post-hoc analysis of study 3 iloperidone 12–24 and 
20–24 mg/day was shown to be equivalent to risperidone 
6–8 mg/day.51 After six weeks’ treatment no significant differ-
ences was found in changes from baseline for PANSS-T and 
BPRS scores. Results were similar comparing iloperidone 
12 mg/day with haloperidol 15 mg/day in a post hoc analysis 
of four six-week studies.52
Long-term efficacy
Long-term efficacy was evaluated in three 52-week prospec-
tive, double-blind, randomized non-inferiority studies.50 After 
a six-week stabilization phase, patients entered a 46-week, 
long-term, double-blind maintenance phase. Of 1644 random-
ized patients, 1326 completed the stabilization phase: 473 
(359 iloperidone and 114 haloperidol) were included in the 
long-term efficacy analysis. The primary efficacy endpoint 
was time to relapse, defined as an increase in the PANSS-T 
score of 25% or more from the start of the long-term phase; 
discontinuation because of lack of efficacy; aggravated psy-
chosis with hospitalization; or a 2-point or greater increase in 
the clinical global impression of change (CGI-C) score after 
week 6. Iloperidone was non-inferior to haloperidol within 
the stated non-inferiority margin. Rates of relapse differed 
only slightly between iloperidone (43.5%) and haloperidol 
(41.2%), and reasons for relapse were similar as well. The 
most common reasons for discontinuation were withdrawal 
of consent (14.8% for iloperidone and 8.5% for haloperidol: 
number needed to treat (NNT) 16, not significant) and unsat-
isfactory therapeutic effect (11.1% and 9.3%: NNT 56, not 
significant). Mean time to relapse was 89.8 days for iloperi-
done (median 50 days) and 101.8 days for haloperidol (median 
78 days): however, these differences were not significant.
Efficacy and single nucleotide polymorphisms
The presence of the null FS63TER allele of the rs18000169 
polymorphism in the gene encoding the ciliary neurotropic 
factor (CNTF) may potentially increase the risk of schizo-
phrenia. In a four-week randomized, double-blind, placebo- 
and active controlled inpatient study Lavedan and colleagues 
compared the efficacy of iloperidone 24 mg/day with placebo. 
Iloperidone was significantly more effective in improving Drug Design, Development and Therapy 2010:4 42
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PANSS-T, PANSS-P, PANSS-negative (N), BPRS, Clinical 
Global Impression of Change (CGI-C), and Clinical Global 
Impression of Severity (CGI-S) scores in schizophrenic 
inpatients. Iloperidone was significantly more effective than 
placebo across all measures in patients who were homozygote 
to G/G for CNTF rs1800169 G/C polymorphism. Patients 
with the non-G/G genotype responded similarly to iloperi-
done and placebo.53
More recently, genotypes of 407 patients were analyzed 
for 334,563 single nucleotide polymorphisms (SNPs). SNPs 
associated with iloperidone efficacy (based on changes in 
mean PANSS-T scores) were identified within the neuronal 
PAS domain protein 3 gene (NPAS3), close to a transloca-
tion breakpoint site previously observed in a family with 
schizophrenia. Five other loci were associated with changes 
in mean PANSS-T scores after treatment with iloperidone, 
including the XK, Kell blood group complex subunit-related 
family, member 4 gene (XKR4), the tenascin-R gene (TNR), 
the glutamate receptor, inotropic, AMPA 4 gene (GRIA4), 
the glial cell line-derived neurotrophic factor receptor-alpha2 
gene (GFRA2), and the NUDT9P1 pseudogene located in 
the chromosomal region of the serotonin receptor 7 gene 
(HTR7).54 In the subsequent 28-day inpatients randomized, 
double-blind, placebo and ziprasidone study application of 
the six-marker genotype combinations defined four groups 
of patients with distinct probabilities of response. More than 
75% of iloperidone-treated patients in the group with optimal 
genotype combinations showed a 20% or greater improve-
ment, compared with 37% for patients with other genotypes. 
The results illustrated the combined use of genetic markers 
to predict enhanced response to iloperidone, supporting the 
application of pharmacogenetics to individualize treatments 
for schizophrenia.55
Safety and tolerability
Common adverse events
Iloperidone’s safety profile was evaluated in double-blind 
phase III short-term trials.18,48 As mentioned, drugs used 
as comparators were haloperidol (study 1), risperidone 
(studies 2 and 3) or ziprasidone, and placebo. Studies 1–3 
have been recently reviewed48 (see also Table 3). The most 
frequent adverse events (AEs) with iloperidone were diz-
ziness, dry mouth, dyspepsia and somnolence; except for 
dyspepsia, a relationship with dose was possible. Discon-
tinuation due to AEs was 4.8% for iloperidone, 7.6% for 
haloperidol, 6.2% for risperidone, and 4.8% for placebo.48 
Findings were similar in the ziprasidone-controlled trial 
in patients with acute exacerbations of schizophrenia.49 
Although, iloperidone gave lover rates of some particularly 
troublesome AEs (eg, sedation, somnolence, EPS, akathisia, 
agitation and restlessness) it had higher rates of tachycardia 
and orthostatic hypotension than ziprasidone. The rate of 
orthostatic hypotension was also highest with iloperidone 
(19.5%) in the risperidone-and haloperidol-controlled trials 
(mostly within the first week of treatment and generally not 
lasting); no significant changes in blood pressure occurred 
with haloperidol, risperidone, and placebo.48–50 Iloperidone 
was also associated with higher rates of mean weight gain and 
the incidence of clinically significant gain was greater than 
with ziprasidone. Weight increase with iloperidone in this 
study was slightly higher than the 1.7 kg increase and 15.2% 
rate of clinically significant weight gain after 20–24 mg/day 
in the risperidone- and haloperidol-controlled trials.48,49
Long term safety was checked in the three 52-week 
trials, in comparison with haloperidol.50 Results were con-
sistent with short-term findings;48,49 there were no significant 
differences between week 6 and week 52, with only a slight 
increase in the rate of patients experiencing at least one AEs 
with iloperidone, which rose from 68.6% to73.3%, and a 
small decrease with haloperidol, from 79.9% to 68.6%. 
Aggravation of schizophrenia and psychosis were the most 
common serious AE and were more frequent with iloperidone 
(18.1% versus 16.1% with haloperidol). Most of the weight 
gain in patients given iloperidone was during the first weeks, 
after which there were only minimal additional increases.50
ePS and akathisia
In the short-term studies EPS was assessed using the Extrapy-
ramidal Symptom Rating subscale (ESRS). Results have been 
reviewed elsewhere.48,49 Overall rating of EPS in the three 
six-week, placebo and haloperidol/risperidone-controlled tri-
als indicated improvement from baseline to end-point with all 
iloperidone doses (4–8, 10–16 and 20–24 mg/day). This was 
in sharp contrast to haloperidol (15 mg/day), which showed 
worsening in most of the ESRS subscales. Worsening of 
akathisia, evaluated using the Barnes Akathisia Scale (BAS), 
was less frequent with iloperidone than with haloperidol and 
risperidone (4–8 mg/day) but was not significantly different 
from placebo (see also Table 3).48 In the four-week, placebo 
and ziprasidone-controlled trial iloperidone (24 mg/day) 
was not associated with any increase in akathisia, and more 
patients experienced significant improvement than with 
placebo. Again, the incidence of EPS was low and not 
significantly different from placebo, whereas ziprasidone 
(160 mg/day) was associated with significant worsening in 
the clinical impression of severity of akathisia.49Drug Design, Development and Therapy 2010:4 43
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Table 3 Main adverse drug reactions reported in clinical trials
Short term safety trial49 (4 weeks)
Iloperidone 24 mg/day  
(n = 295)
Ziprasidone 160 mg/day  
(n = 149)
Placebo (n = 149)
ePS (%) 3 9 2
Akathisia (%) 1 7 0
Mean changes from baseline
Orthostatic hypotension (%) 7 0 2
QTc prolongation (msec)  11.4 11.3 0
(mean maximum) 16.2  12.3  -2.4 
weight gain (kg) 2.8 1.1 0.5
Total cholesterol (mg/dL) 8.1 4.1 -0.5
Triglycerides (mg/dL) 0.8 4.6 19.5
Glucose (mg/dL) 7.9 4.7 3.2
Prolactin (ng/mL) 2.6 1.9 -6.3
Short-term safety trials48 (6 weeks)
Iloperidone 4–24 mg/day  
(n = 1044)
Haloperidol 15 mg/day  
(n = 118)
Risperidone 4–8 mg/day  
(n = 306)
Placebo (n = 440)
ePS (%) 4–5.4 20.3 9.5 4.8
Akathisia (%) 1.5–4.8 13.6 6.9 3.6
Mean changes from baseline
Orthostatic hypotension (%) 19.5 15.3 12.0 8.3
QTc prolongation (msec) 2.9–9.1 5.0 0.6 0
weight gain (kg) 1.5–2.1 -0.1 1.5 -0.3
Total cholesterol (mg/dL) 0.0 0.0 -3.9 -7.7
Triglycerides (mg/dL) -26.5 0.0 -26.5 -35.4
Glucose (mg/dL) 7.2–16.2 10.8 3.6 -3.6
Prolactin (µg/L) -38.0/-23.1 115.8 214.5 -57.4
Long-term safety trials50 (Data at 6 week)
  Iloperidone 4–16 mg/day (n = 1231) Haloperidol 5–20 mg/day (n = 403)
ePS (%) 0.6 7.7
Akathisia (%) 3.5 18.6
Mean changes from baseline
Orthostatic hypotension (%) NA NA
QTc prolongation (msec) 3.2 4.0
weight gain (kg) 2.6 0.6
Total cholesterol (mg/dL) -0.3 7.4
Triglycerides (mg/dL) 0.3 -0.1
Glucose (mg/dL) 2.7 -0.4
Prolactin (ng/mL) NA NA
Long-term safety trials50 (Data at 52 weeks)
  Iloperidone 4–16 mg/day (n = 371) Haloperidol 5–20 mg/day (n = 118)
ePS (%) 0.8 5.9
Akathisia (%) 3.8 14.4
Mean changes from baseline
Orthostatic hypotension (%) NA NA
QTc prolongation (msec) 10.3 9.4
weight gain (kg) 3.8 2.3
Total cholesterol (mg/dL) 0.9 6.9
Triglycerides (mg/dL) 6.8 12.1
Glucose (mg/dL) 5.8 -0.5
Prolactin (ng/mL) NA NA
Abbreviations: ePS, extrapyramidal symptoms; NA, not available.Drug Design, Development and Therapy 2010:4 44
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The long-term haloperidol-controlled trial substantiated 
the favorable safety profile of iloperidone. Overall rating of 
EPS at the end of the maintenance phase indicated improve-
ment in 48.2% of patients treated with iloperidone (4 to 
16 mg/day) compared with 34.7% of those given haloperidol 
(5 to 20 mg/day); worsening of symptoms was reported in 
13.5% of patients receiving iloperidone and 36.4% receiving 
haloperidol. Akathisia was also worse with haloperidol, 
being reported in 3.5% with iloperidone and 18.6% with 
haloperidol at week 6 and in 14.4% and 3.8% after 52 weeks. 
The overall rating of akathisia, assessed by the BAS at study 
end-point, indicated improvement in 24.3% with iloperidone 
compared to 16.9% of patients who received haloperidol. 
Worsening was noted in respectively 9.2% and 23.7%.50
QT interval
The mean changes in corrected QTc intervals using 
Fridericia’s correction were calculated for patients during 
the short- and long-term trials. In the six-week acute-phase 
trials the QTc prolongation with iloperidone was dose-
related, increasing from 2.9 milliseconds after 4–8 mg to 
9.1 milliseconds after 20–24 mg. QTc prolongation aver-
aged respectively 5.0 and 0.6 milliseconds with haloperidol 
and risperidone. In the ziprasidone-controlled trial the 
mean prolongation from baseline at study midpoint was 
11.4 milliseconds with iloperidone and 11.3 milliseconds with 
ziprasidone. Mean maximum changes in the QTc interval 
were similar with iloperidone and ziprasidone, both being 
significantly greater than with placebo (-2.4 milliseconds). 
Two iloperidone-treated and one ziprasidone-treated patient 
had 15% increases in QTc intervals. No patients with a 
QTc interval 500 milliseconds at baseline experienced a 
change to 500 milliseconds.49
In the long-term pooled analysis the changes of QTc 
interval associated to iloperidone were similar to haloperi-
dol: 3.2 milliseconds and 4.0 respectively at week 6, and 
10.3 and 9.4 milliseconds at the end-point.50 Importantly, 
haloperidol as well as risperidone are included in the list 
of drugs to be avoided for use in patients with diagnosed 
or suspected congenital long QT syndrome, because of the 
risk of torsades de pointes (Tdp) (a list of drugs associated 
with TdP is available at http://www.torsades.org). So, like 
its comparators, the use of iloperidone might be limited by 
concern about cardiovascular consequences, requiring careful 
monitoring of cardiac function.
Interestingly, DNA polymorphisms associated with 
QTc prolongation have been identified in several loci, 
including the ceramine kinase-like (CERKL) gene, which 
is part of the ceramide pathway, involved in the regulation 
of transmembrane currents. Accordingly, in recent studies, 
iloperidone- and ziprasidone-treated patients and placebo 
patients were all genotyped for CERKL protein SNP. Two 
SNPs within intron 2 of the CERKL gene, rs993648 and 
rs1441162, were significantly associated with QTc pro-
longation in iloperidone-patients. At steady-state, patients 
heterozygous for the rs993648 SNP had a QTc interval of 
4.5 milliseconds, whereas patients homozygous for this SNP 
had a significantly longer QTc interval, 17.8 milliseconds. 
In ziprasidone-treated patients none of the SNPs showed any 
correlation with QTc prolongation. The authors concluded 
that assessing the CERKL gene in patients taking iloperidone 
could help predict whether they were likely to experience 
QTc prolongation.56
Metabolic side effects
In the six-week acute-phase trials mild changes in glucose 
levels were observed in all groups; 7.2 mg/dL, 9.0 mg/dL 
and 16.2 mg/dL respectively with iloperidone 4–8 mg/day, 
10–16 mg/day and 20–24 mg/day, 3.6 mg/dL with risperidone 
and 10.8 mg/dL with haloperidol. Changes in total cholesterol 
levels were negligible in all treatment groups. Prolactin content 
decreased of 38 µg/L and 23.1 µg/L with iloperidone 4–8 and 
10–16 mg/day (results were not available for the 20–24 mg/day 
dose) but increased with both haloperidol (15 mg/day) and 
risperidone (4–8 mg/day) (Table 3), which decreased from 
38 µg/L and 23.1 µg/L with iloperidone 10–16 mg/day.48 
Similar findings were observed in the ziprasidone-controlled 
study, where the incidence of small changes in laboratory 
parameters was comparable for the active drugs.49
Long-term iloperidone also caused slight increases in 
total cholesterol, triglycerides and glucose, and the change 
in glucose was higher than with haloperidol; no information 
was collected about iloperidone’s effects of on prolactin.50
Special populations
Information on the pharmacokinetics of iloperidone in 
children and adolescents, and on its safety and effectiveness 
compared to adults is lacking.33 Information on the pharma-
cokinetics and pharmacodynamics in the elderly compared 
to younger healthy subjects is also limited. A phase II ran-
domized, double-blind, placebo-controlled trial evaluated 
the tolerability and safety of iloperidone (0.5–6 mg/day in 
two divided doses) in elderly patients with dementia and 
psychotic and behavioral disturbances. Iloperidone was well 
tolerated and safe up to 6 mg/day.36 Other studies in elderly 
patients with psychosis associated with Alzheimer’s disease Drug Design, Development and Therapy 2010:4 45
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suggested there may be different tolerability profiles in this 
population and younger patients with schizophrenia.33
Renal impairment does not significantly change iloperi-
done pharmacokinetics after single dose (3 mg), reflecting 
its extensive hepatic metabolism (less than 1% of the drug is 
excreted unchanged). Mean maximum plasma concentrations 
of its main metabolites too were only minimally affected by 
renal impairment (creatinine clearance 30 mL/min) after 
a 3 mg single dose; mean AUC was reduced by only 6% for 
reduced iloperidone and increased by 52% for the inactive 
P95-1213 compared to healthy subjects.33,34
The effects of hepatic impairment on iloperidone 
pharmacokinetics are not yet clear,34 but a recent abstract 
suggested that exposure to the active reduced iloperidone 
markedly increased in mild or moderate hepatic-impaired 
patients compared with matched healthy subjects after a 
single iloperidone dose (2 mg). Iloperidone should therefore 
not be given to people with mild, moderate or severe hepatic 
impairment, especially if a CYP2D6 deficiency is suspected 
or drugs that inhibit CYP2D6 or induce or inhibit CYP3A 
are added to or subtracted from iloperidone.33
As mentioned, PM of CYP2D6 have higher exposure 
to iloperidone and its main metabolites compared with EM 
subjects;33 it is about 47% higher for the parent drug, 85% for 
the reduced metabolite and 85% for the inactive metabolite.34 
Aripiprazole, rioperidone and sertindole too present poly-
morphic metabolism characteristics mirroring the CYP2D6 
phenotype,21,57 although for risperidone the concentrations of 
the active fraction (parent drug + active metabolite) varied 
little between EM and PM at CYP2D6.43
Interestingly, recent studies not yet published in full have 
identified variant CYP2D6 genotypes that result in higher-
than-normal exposure to iloperidone. These have investigated 
the association between the CYP2D6 1846GA polymor-
phism, which is associated with the CYP2D6*4 allele and 
includes the GG (wild-type), AA, AG, and GA genotypes, 
and the degree of QTc interval prolongation. The study drew 
on 74 patients enrolled in an open-label safety study of ilo-
peridone and classified them as normal (GG), intermediate 
(AG) and poor metabolizers (AA) of this drug, based on 
the plasma iloperidone-to-metabolite concentration ratios 
(iloperidone + active metabolite/inactive metabolite). Expo-
sure to the active drug was greater in patients with the AA 
genotype. After 14 days of iloperidone treatment, the QTc 
prolongation in intermediate/poor metabolizers (AG/AA) 
was 15 milliseconds compared to 10.4 milliseconds in GG 
patients (P = 0.008). Patients with either genotype showed 
adaptation with continued treatment and after 28 days the 
QTc prolongation was 12.9 milliseconds and 5 milliseconds 
in AG/AA and GG patients. Thus at steady state iloperidone 
CYP2D6 polymorphism was associated with exposure to the 
drug, and this correlated with different metabolic ratios that 
result in different QTc prolongation.58
As mentioned, other pharmacogenetic studies of iloperi-
done have also identified biomarkers that may assist clini-
cians in predicting treatment response and AE. These have 
provided new information on efficacy and adverse reactions 
to iloperidone, with the goal of predicting which patients 
are likely to have the best benefit-to-risk ratio QTc ratio for 
prolongation after iloperidone (for reviews see31,59).
Conclusions
Like other second-generation antipsychotics, iloperidone has 
high affinity for 5-HT2A receptors and α1 adrenergic receptors 
and moderate affinity for D2 receptors and is recommended 
for the acute treatment of adult schizophrenic patients. Based 
on efficacy studies the recommended starting dose was 1 mg 
b.i.d, which can be titrated by daily increases to 12–24 mg/day 
up to the recommended target dose, although the optimal 
duration of therapy remains to be established. Doses should 
be halved for concomitant administration with strong 
CYP2D6 and CYP3A4 inhibitors. Similarly, PM of CYP2D6 
have higher exposure to iloperidone than EM subjects, and 
dosing adjustment is needed. Iloperidone’s efficacy was also 
assessed in relation to specific genetic profiling. Preliminary 
data suggest that several putative SNPs may be associated 
with an enhanced response to iloperidone although further 
studies are needed before these polymorphisms can be used 
to individualize iloperidone treatment schedule.
As reviewed elsewhere,31,38 a pharmacodynamic-
pharmacokinetic correlation was tentatively established for 
this drug, with the minimal effective concentration appear-
ing to be 5 ng/mL in patients with schizophrenia. However, 
iloperidone is extensively metabolized to reduced iloperidone 
and the metabolite-to-parent drug ratio varies with endog-
enous and exogenous factors affecting the patient’s metabolic 
status, this probably being the main source of iloperidone 
pharmacokinetic variability within and between populations.
Information on the efficacy and safety of iloperidone 
in potentially at-risk populations such as children and ado-
lescents, elderly patients, and subjects with impaired organ 
function is still limited or lacking.
Although iloperidone was effective and generally well 
tolerated in several controlled short and longer trials – showing 
greater efficacy than placebo and indirectly comparable 
to either first- or second-generation drugs on positive and Drug Design, Development and Therapy 2010:4 46
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negative symptoms of schizophrenia – these enrolled only 
small numbers of highly selected patients, with a non-inferior-
ity design, and lacking any direct “head-to-head” comparison 
with other second-generation antipsychotic agents. The studies 
comparing iloperidone with risperidone and ziprasidone were 
not designed to test these different antipsychotics directly. 
These weaknesses limit the general extension of the results 
to patients with other psychological or clinical comorbidities, 
those with comorbid drug use and/or dependence, those resis-
tant to treatment with other antipsychotics, and adolescents or 
elderly patients. Moreover, data are limited on iloperidone’s 
effectiveness in the maintenance treatment of schizophrenia. 
The only available data demonstrated non-inferiority to halo-
peridol in a subsample of responsive patients. Lacking direct 
comparative data, it is difficult to define the place in therapy 
of this new agent in the treatment of schizophrenia. Lack of 
direct comparative assessment, slow initial titration, twice-
daily administration, and cost are all significant obstacles to 
considering iloperidone for first-line therapy in schizophrenia. 
Further well designed comparative studies are now needed to 
clarify the therapeutic role and advantages of the new anti-
psychotic agent in terms of efficacy and safety.
Although iloperidone appears to have a favorable 
safety profile as regards to the minimal EPS and metabolic 
syndrome observed in clinical trials, the effect on the QT 
interval is of concern. Prolongation of QT interval is com-
parable to that with ziprasidone, which was not licensed in 
the UK because of concerns about potential cardiotoxicity. 
QT interval prolongation is the best available predictor for 
TdP episodes and is considered a risk factor for sudden 
cardiac death. A rising number of structurally unrelated and 
non-cardiovascular drugs prolong the QT interval and this is 
the most common cause of withdrawal or restriction of the 
use of drugs on the market.60,61 Drugs that may cause TdP at 
therapeutic dosages, such as sotalol, dofetilide or ibutile, can 
prolong the QT interval by more than 50 milliseconds, while 
the maximum prolongation of QT interval with iloperidone is 
considerably less (16.2 milliseconds). However, iloperidone, 
like any new drug, has been tested only in small samples of 
patients and the risk of TdP in the general population remains 
unknown. This risk is in fact associated to the risk of drug 
interaction and to the number and characteristics of patients 
exposed to the treatment in clinical practice. A small increase 
in the QT interval can lead to fatal arrhythmias.
Before prescribing iloperidone therefore clinicians 
must consider risk factors for drug-induced TdP including 
female sex, cardiac hypertrophy, heart failure, bradycardia, 
electrolyte imbalances (hypokalemia, hypocalcemia), 
congenital QT syndrome and pharmacodynamic and 
pharmacokinetic drug interactions. As mentioned, the effect 
on the QT interval is amplified by inhibition of iloperidone 
metabolism and polymorphism of CYP2D6 could further 
affect its metabolism increasing the risk of TdP. So several 
factors must be considered in order to avoid cardiac events 
and to personalize medicine in schizophrenic patients accord-
ing to specific genotypes. Finally, the role of post-marketing 
surveillance is important and should monitor iloperidone for 
arrhythmias or TdP, identifying any early warning signs.
The clinical advantages of the new antipsychotic agents 
are not well evaluated by direct superiority comparative 
studies. The lack of such evidence adds to the difficulty of 
establishing the place in therapy of iloperidone and the other 
new agents, and providing clinicians with clear indications to 
guide the choice of the best treatment for each schizophrenic 
patient. Well designed, and appropriately powered clinical and 
pharmacogenetic studies are now needed to clinically assess 
the therapeutic role of iloperidone in schizophrenia.
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